| Autor: |
Yisheng Sun, Qiaomin Li, Yuanyuan Luo, Hanping Zhu, Fang Xu, Hangjing Lu, Pingping Yao, Zhen Wang, Wenbin Zhao, Zhan Zhou |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Vaccine: X, Vol 16, Iss , Pp 100444- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2590-1362 |
| DOI: |
10.1016/j.jvacx.2024.100444 |
| Popis: |
Although the global pandemic of SARS-CoV-2 has passed, there are still regional outbreaks that continue to jeopardize human health. Hence, there is still a great deal of interest in developing an efficient vaccine that can quickly and effectively prevent reemerging outbreaks of SARS-CoV-2. Delta variant was once a dominant strain in the world in 2021, and we first constructed a recombinant RBDdelta-Fc fusion vaccine by coupling the RBD of Delta variant with the human Fc fragment. This Fc fusion strategy increases the immunogenicity of the recombinant RBD vaccine, with a long-lasting high level of IgG antibodies and neutralizing antibodies induced by RBDdelta-Fc vaccine. This RBDdelta-Fc vaccine, as well as the RBD-Fc vaccine prepared in our previously study, could trigger a durable immune effect by the heterologous boosting immunity, and the RBD-Fc induced a quicker humoral immune response than the homologous immunization with inactivated vaccines. In conclusion, the Fc fusion strategy has a significant role in enhancing the immunogenicity of recombinant protein vaccines, thus promising the development of a safe and efficient vaccine for the heterologous boosting against SARS-CoV-2. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
